CBD Life Sciences Inc.
CBDLOTCHealthcare● Active
$0.00
$-0.00(-16.67%)
Market Cap$469243
P/E Ratio—
52W High$0.001
52W Low$0.0001
CBD Life Sciences Inc. (CBDL) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CBDL · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.10M | $0.11M | $0.17M | $0.16M | $0.06M |
| Cost of Revenue | $0.06M | $0.12M | $0.20M | $0.44M | $0.21M |
| Gross Profit | $0.04M | ($0.01M) | ($0.03M) | ($0.28M) | ($0.15M) |
| Gross Margin %(computed) | 42.20% | -9.08% | -18.31% | -174.90% | -250.18% |
| Operating Expenses | |||||
| R&D Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| G&A Expenses | $0.00M | $0.00M | $0.03M | $0.17M | $1.39M |
| Total Operating Expenses | $0.14M | $0.75M | $0.05M | $0.58M | $4.98M |
| Operating Income | ($0.10M) | ($0.76M) | ($0.08M) | ($0.86M) | ($5.13M) |
| Operating Margin %(computed) | -103.44% | -695.36% | -47.01% | -536.57% | — |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($0.05M) | ($0.76M) | ($0.08M) | ($0.86M) | ($5.13M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($0.05M) | ($0.76M) | ($0.08M) | ($0.86M) | ($5.13M) |
| Net Margin %(computed) | -49.76% | -695.36% | -47.01% | -536.57% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 |
| Wtd Avg Shares | 4109.97M | 3097.31M | 135.69M | 4070.62M | 1229.74M |
| EBITDA | ($0.10M) | ($0.70M) | ($0.02M) | ($0.81M) | ($4.89M) |
| EBITDA Margin %(computed) | -103.44% | -644.34% | -13.77% | -503.15% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more CBD Life Sciences Inc. data
About CBD Life Sciences Inc. (CBDL) Income Statement
CBD Life Sciences Inc. (CBDL) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CBDL reported revenue of $0.00B, gross profit of $0.00B (gross margin 42.20%), and net income of ($0.00B) — a net profit margin of -49.76%.
Frequently asked questions
CBDL · 4 questionsCBD Life Sciences Inc. (CBDL) reported revenue of $0.00B for 2025, down 9.7% year-over-year.
CBDL revenueCBDL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09